Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

M. Ferro, G. Di Lorenzo, M. D. Vartolomei, D. Bruzzese, F. Cantiello, G. Lucarelli, G. Musi, S. Di Stasi, R. Hurle, G. Guazzoni, G. M. Busetto, A. Gabriele, F. Del Giudice, R. Damiano, F. Perri, S. Perdona, P. Verze, M. Borghesi, R. Schiavina, G. L. Almeida & 18 others P. Bove, E. Lima, R. Autorino, N. Crisan, A. R.Abu Farhan, M. Battaglia, G. I. Russo, Vincenzo Ieluzzi, G. Morgia, P. De Placido, D. Terracciano, A. Cimmino, L. Scafuri, V. Mirone, O. De Cobelli, S. Shariat, Guru Sonpavde, C. Buonerba

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.

Original languageEnglish
JournalWorld Journal of Urology
DOIs
Publication statusE-pub ahead of print - Jan 1 2019

Fingerprint

Basophils
Mycobacterium bovis
Urinary Bladder Neoplasms
Bacillus
Recurrence
Eosinophils
Monocytes
Muscle Neoplasms
Proportional Hazards Models
Medical Records
Multivariate Analysis
Retrospective Studies
Confidence Intervals
Survival

Keywords

  • Basophils
  • BCG
  • Bladder cancer

ASJC Scopus subject areas

  • Urology

Cite this

Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. / Ferro, M.; Di Lorenzo, G.; Vartolomei, M. D.; Bruzzese, D.; Cantiello, F.; Lucarelli, G.; Musi, G.; Di Stasi, S.; Hurle, R.; Guazzoni, G.; Busetto, G. M.; Gabriele, A.; Del Giudice, F.; Damiano, R.; Perri, F.; Perdona, S.; Verze, P.; Borghesi, M.; Schiavina, R.; Almeida, G. L.; Bove, P.; Lima, E.; Autorino, R.; Crisan, N.; Farhan, A. R.Abu; Battaglia, M.; Russo, G. I.; Ieluzzi, Vincenzo; Morgia, G.; De Placido, P.; Terracciano, D.; Cimmino, A.; Scafuri, L.; Mirone, V.; De Cobelli, O.; Shariat, S.; Sonpavde, Guru; Buonerba, C.

In: World Journal of Urology, 01.01.2019.

Research output: Contribution to journalArticle

Ferro, M, Di Lorenzo, G, Vartolomei, MD, Bruzzese, D, Cantiello, F, Lucarelli, G, Musi, G, Di Stasi, S, Hurle, R, Guazzoni, G, Busetto, GM, Gabriele, A, Del Giudice, F, Damiano, R, Perri, F, Perdona, S, Verze, P, Borghesi, M, Schiavina, R, Almeida, GL, Bove, P, Lima, E, Autorino, R, Crisan, N, Farhan, ARA, Battaglia, M, Russo, GI, Ieluzzi, V, Morgia, G, De Placido, P, Terracciano, D, Cimmino, A, Scafuri, L, Mirone, V, De Cobelli, O, Shariat, S, Sonpavde, G & Buonerba, C 2019, 'Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor', World Journal of Urology. https://doi.org/10.1007/s00345-019-02754-2
Ferro, M. ; Di Lorenzo, G. ; Vartolomei, M. D. ; Bruzzese, D. ; Cantiello, F. ; Lucarelli, G. ; Musi, G. ; Di Stasi, S. ; Hurle, R. ; Guazzoni, G. ; Busetto, G. M. ; Gabriele, A. ; Del Giudice, F. ; Damiano, R. ; Perri, F. ; Perdona, S. ; Verze, P. ; Borghesi, M. ; Schiavina, R. ; Almeida, G. L. ; Bove, P. ; Lima, E. ; Autorino, R. ; Crisan, N. ; Farhan, A. R.Abu ; Battaglia, M. ; Russo, G. I. ; Ieluzzi, Vincenzo ; Morgia, G. ; De Placido, P. ; Terracciano, D. ; Cimmino, A. ; Scafuri, L. ; Mirone, V. ; De Cobelli, O. ; Shariat, S. ; Sonpavde, Guru ; Buonerba, C. / Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. In: World Journal of Urology. 2019.
@article{cdf9fb6b56d74666a1e3aef62f57c5ae,
title = "Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Gu{\'e}rin after transurethral resection of the bladder tumor",
abstract = "Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9{\%}) recurrences, 303 (29.0{\%}) progressions and 150 (14.3{\%}) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30{\%} increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95{\%} confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.",
keywords = "Basophils, BCG, Bladder cancer",
author = "M. Ferro and {Di Lorenzo}, G. and Vartolomei, {M. D.} and D. Bruzzese and F. Cantiello and G. Lucarelli and G. Musi and {Di Stasi}, S. and R. Hurle and G. Guazzoni and Busetto, {G. M.} and A. Gabriele and {Del Giudice}, F. and R. Damiano and F. Perri and S. Perdona and P. Verze and M. Borghesi and R. Schiavina and Almeida, {G. L.} and P. Bove and E. Lima and R. Autorino and N. Crisan and Farhan, {A. R.Abu} and M. Battaglia and Russo, {G. I.} and Vincenzo Ieluzzi and G. Morgia and {De Placido}, P. and D. Terracciano and A. Cimmino and L. Scafuri and V. Mirone and {De Cobelli}, O. and S. Shariat and Guru Sonpavde and C. Buonerba",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00345-019-02754-2",
language = "English",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

AU - Ferro, M.

AU - Di Lorenzo, G.

AU - Vartolomei, M. D.

AU - Bruzzese, D.

AU - Cantiello, F.

AU - Lucarelli, G.

AU - Musi, G.

AU - Di Stasi, S.

AU - Hurle, R.

AU - Guazzoni, G.

AU - Busetto, G. M.

AU - Gabriele, A.

AU - Del Giudice, F.

AU - Damiano, R.

AU - Perri, F.

AU - Perdona, S.

AU - Verze, P.

AU - Borghesi, M.

AU - Schiavina, R.

AU - Almeida, G. L.

AU - Bove, P.

AU - Lima, E.

AU - Autorino, R.

AU - Crisan, N.

AU - Farhan, A. R.Abu

AU - Battaglia, M.

AU - Russo, G. I.

AU - Ieluzzi, Vincenzo

AU - Morgia, G.

AU - De Placido, P.

AU - Terracciano, D.

AU - Cimmino, A.

AU - Scafuri, L.

AU - Mirone, V.

AU - De Cobelli, O.

AU - Shariat, S.

AU - Sonpavde, Guru

AU - Buonerba, C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.

AB - Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.

KW - Basophils

KW - BCG

KW - Bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=85064646644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064646644&partnerID=8YFLogxK

U2 - 10.1007/s00345-019-02754-2

DO - 10.1007/s00345-019-02754-2

M3 - Article

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -